Cancer Genetics, Inc. (CGIX) is a tTiny company with exploding revenue and operating profit growth...but it is still cash flow negative. The drugs target diseases with unknown success rates. If effective, this stock moves higher. Chances are low so beware of chasing the stock. $CGIX, Cancer Genetics, Inc. / D The company reported a drop in cash. Cash of $9.5 million as compared to $19.5 million at December 31, 2015. $12M debt re-financing helps on liquidity, though debt/equity ratio is not excessive. Better liquidity is always desired for a company but CGIX must report another few quarters of profitability growth before justifying its two-bagger jump.Related:Valeant Pharma (VRX) and Synergy Pharma (SGYP) are on the mend.Facebook PT $165Valeant: More Volatility Ahead